Evidence map›Paper›PMID 36724829›Full record

ArticleJournal of molecular and cellular cardiology2023

The lack of Troponin I Ser-23/24 phosphorylation is detrimental to in vivo cardiac function and exacerbates cardiac disease.

Hussam E Salhi, Vikram Shettigar, Lorien Salyer, Sarah Sturgill, Elizabeth A Brundage, Joel Robinett, Zhaobin Xu, Eaman Abay, Jeovanna Lowe, Paul M L Janssen and 4 more

Open access · greenAbstract read
In one paragraph

Article in Journal of molecular and cellular cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Roles of cMyBP-C phosphorylation on cardiac contractile dysfunction inJournal of molecular and cellular cardiology plus · 2024
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Hussam E SalhiDepartment of Physiology and Cell Biology and Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, United States of America.
Vikram ShettigarDepartment of Physiology and Cell Biology and Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, United States of America.
Lorien SalyerDepartment of Physiology and Cell Biology and Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, United States of America.
Sarah SturgillDepartment of Physiology and Cell Biology and Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, United States of America.
Elizabeth A BrundageDepartment of Physiology and Cell Biology and Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, United States of America.
Joel RobinettDepartment of Physiology and Cell Biology and Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, United States of America.
Zhaobin XuDepartment of Physiology and Cell Biology and Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, United States of America.
Eaman AbayDepartment of Physiology and Cell Biology and Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, United States of America.
Jeovanna LoweDepartment of Physiology and Cell Biology and Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, United States of America.
Paul M L JanssenDepartment of Physiology and Cell Biology and Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, United States of America.
Jill A Rafael-FortneyDepartment of Physiology and Cell Biology and Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, United States of America.
Noah WeislederDepartment of Physiology and Cell Biology and Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, United States of America.
Mark T ZioloDepartment of Physiology and Cell Biology and Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, United States of America.
Brandon J BiesiadeckiDepartment of Physiology and Cell Biology and Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH, United States of America. Electronic address: Brandon.Biesiadecki@osumc.edu.
Lung Institute · USThe Ohio State University · US

Funding

Integrated Crosstalk of Thin Filament Post-translational ModificationsR01HL114940 · NHLBI · OHIO STATE UNIVERSITY · PI BIESIADECKI, BRANDON J · 2013 to 2021
$3.6M
BAT as a therapeutic for the metabolic and cardiac dysfunction with senescence.R01AG060542 · NIA · OHIO STATE UNIVERSITY · PI COEN, PAUL MARTIN, STANFORD, KRISTIN I · 2019 to 2023
$3.0M
Troponin I phosphorylation as a novel novel cardiac inotropeR01HL164795 · NHLBI · OHIO STATE UNIVERSITY · PI Brandon J Biesiadecki · 2023 to 2026
$2.6M
Training To Provide the Knowledge, Skills, and Culture To the Next Generation of Cardiovascular ScientistsT32HL134616 · NHLBI · OHIO STATE UNIVERSITY · PI Brandon J Biesiadecki, Jill A Rafael-Fortney · 2017 to 2026
$2.6M
NHLBI NIH HHS R01 HL114940NHLBI NIH HHS R01 HL164795NHLBI NIH HHS T32 HL134616NIA NIH HHS R01 AG060542
6 · The paper itself

Abstract

Troponin I (TnI) is a key regulator of cardiac contraction and relaxation with TnI Ser-23/24 phosphorylation serving as a myofilament mechanism to modulate cardiac function. Basal cardiac TnI Ser-23/24 phosphorylation is high such that both increased and decreased TnI phosphorylation may modulate cardiac function. While the effects of increasing TnI Ser-23/24 phosphorylation on heart function are well established, the effects of decreasing TnI Ser-23/24 phosphorylation are not clear. To understand the in vivo role of decreased TnI Ser-23/24 phosphorylation, mice expressing TnI with Ser-23/24 mutated to alanine (TnI S23/24A) that lack the ability to be phosphorylated at these residues were subjected to echocardiography and pressure-volume hemodynamic measurements in the absence or presence of physiological (pacing increasing heart rate or adrenergic stimulation) or pathological (transverse aortic constriction (TAC)) stress. In the absence of pathological stress, the lack of TnI Ser-23/24 phosphorylation impaired systolic and diastolic function. TnI S23/24A mice also had an impaired systolic and diastolic response upon stimulation increased heart rate and an impaired adrenergic response upon dobutamine infusion. Following pathological cardiac stress induced by TAC, TnI S23/24A mice had a greater increase in ventricular mass, worse diastolic function, and impaired systolic and diastolic function upon increasing heart rate. These findings demonstrate that mice lacking the ability to phosphorylate TnI at Ser-23/24 have impaired in vivo systolic and diastolic cardiac function, a blunted cardiac reserve and a worse response to pathological stress supporting decreased TnI Ser23/24 phosphorylation is a modulator of these processes in vivo.

Indexed as

Heart DiseasesTroponin IAdrenergic AgentsAnimalsCalciumMiceMice, TransgenicMyocardial ContractionPhosphorylationAdrenergic AgentsCalciumTroponin ICardiacHeart rateIn vivoPhosphorylationSympatheticTroponin I

Identifiers

PMID36724829
PMCPMC10074981
OpenAlexW4318426599

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.